Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials

'Eat Well' Produce Prescription RCT

NCT07534501
Recruiting
Conditions Hypertension
Phase NA
Enrollment 1500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This project, conducted within the Department of Veterans Affairs Healthcare System (VHA), will study how a produce prescription (PRx) program called "Eat Well" affects Veterans' health and how often they use healthcare services. About 1 in 4 Veteran households experience food insecurity (FI), which means they do not have reliable access to safe and healthy food. FI can make health worse in many ways, especially for people with conditions like diabetes that need a healthy diet. It also leads to higher healthcare costs. A PRx program, like Eat Well, helps by giving people money or vouchers to buy fruits and vegetables. This study will enroll 1,500 eligible Veterans in North Carolina who will be randomized to receive Eat Well for 6-months, Eat Well for 12-months, or the standard of care. This research will help VA learn important information about using produce prescriptions as a proven way to improve food security.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Eat Well 6-months — Participants will receive $100/month of Eat Well benefits for 6- months and instructions on enrolling in existing VA programs designed to improve health self-management and nutrition education.
  • Behavioral: Eat Well 12-months — Participants will receive $100/month of Eat Well benefits for 12-months and instructions on enrolling in existing VA programs designed to improve health self-management and nutrition education.

Primary Outcomes

  • Systolic blood pressure (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-20
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Medical Research, Inc.
Collaborators: Rockefeller Foundation, Genentech, Inc.
Contact Information
Study Contact:
Study Principal Investigator
(919) 616-6936
Connor.Drake@va.gov
Study Principal Investigator
(919) 616-6936
Connor.Drake@va.gov
Durham VA Health Care System
Connor Drake, PhD
Durham VA Health Care System
Interventions
  • Behavioral: Eat Well 6-months — Participants will receive $100/month of Eat Well benefits for 6- months and instructions on enrolling in existing VA programs designed to improve health self-management and nutrition education.
  • Behavioral: Eat Well 12-months — Participants will receive $100/month of Eat Well benefits for 12-months and instructions on enrolling in existing VA programs designed to improve health self-management and nutrition education.
Study Locations (1 sites)
Durham VA Health Care System, Durham, North Carolina 27705 United States
Eligibility Criteria
Inclusion Criteria: 1. Food Insecurity Risk 2. Hypertension AND diabetes or obesity 3. Hospitalization, ED visit, OR outpatient visit in the past 12-months 4. NC resident 5. Valid email address Exclusion Criteria: * Living in a nursing home or residential facility where meals are prepared
Conditions Hypertension
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aimed to assess and validate the diagnostic utility of a novel Morphology-Voltage-P-wave Score (MVP Score) in identifying left ventricular diastolic dysfunction among patients with hypertension. Researchers will collect information of patient with hypertension and underwent transthoracal echocardiography assessment. The data consist of demographic data, clinical presentation, laboratory, and echocardiography result were collected by two investigators. Then, the data was analyzed by using IBM SPSS Statistics v26.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Echocardiohraphy — Transthoracal echocardiography for diastolic function assessment

Primary Outcomes

  • Diastolic Dysfunction (Up to 1 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-01
Completion: 2025-03-15
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitas Diponegoro
Contact Information
Study Contact:
Leo Deddy Pradipta
+6281316499074
dancingdeagle@gmail.com
Leo Deddy Pradipta
+6281316499074
dancingdeagle@gmail.com
Dr. Kariadi Central General Hospital
Interventions
  • Diagnostic Test: Echocardiohraphy — Transthoracal echocardiography for diastolic function assessment
Study Locations (1 sites)
Dr. Kariadi Central General Hospital, Semarang, Central of Java Indonesia
Eligibility Criteria
Inclusion Criteria: * Essential hypertension Exclusion Criteria: * Secondary or resistant hypertension * LVEF\<55% * Congenital heart disease * Infiltrative cardiomyopathy * Coronary artery disease * Chronic kidney disease * Valvular heart disease * Bundle branch block * Arrhythmia
Conditions High Risk Pregnancy, Arterial Stiffness,...
Phase Not Applicable
Enrollment 2400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Despite advances in obstetric care, preeclampsia (PE) remains the leading cause of maternal death and disability in both developed and developing countries, contributing to over 70,000 maternal and 500,000 fetal deaths annually worldwide. PULSE was designed using a preventative medicine approach, focusing on improving early detection of PE as opposed to managing symptoms after onset. The study aims to uncover the earliest possible signs of PE using a combination of novel clinical tools and established diagnostic techniques to better identify, track, and manage high risk pregnant women. Specifically, PULSE will be examining the incorporation of a non-invasive test for the measurement of arterial stiffness, which has been shown to be predictive of hypertensive disorders. This test, in combination with a wide range of blood biomarkers, detailed ultrasound imaging, and a comprehensive battery of physical and mental health questionnaires, represents the largest, most comprehensive preventative PE study to date. The results of this work has the potential to revolutionize the way PE and other hypertensive disorders of pregnancy are managed and treated and can serve to inform the design of future preventative clinical research studies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Arterial Stiffness and Wave Reflection — Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.

Primary Outcomes

  • Diagnosis of pre-eclampsia (up to 6 weeks post-partum (after delivery))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-07-12
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators: Université de Montréal, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, University of British Columbia, University of Glasgow, Laval University, Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes, McGill University
Principal Investigators:
  • Stella S Daskalopoulou, MD, PhD (PRINCIPAL_INVESTIGATOR) - Research Institute of the McGill University Health Centre
Contact Information
Study Contact:
Helena Papacostas, PhD
514 934-1934
helena.papacostas@rimuhc.ca
Stella S Daskalopoulou, MD, PhD
Royal Victoria Hospital
Interventions
  • Diagnostic Test: Arterial Stiffness and Wave Reflection — Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
Study Locations (1 sites)
Royal Victoria Hospital, Montreal, Quebec H3A 1A1 Canada
Eligibility Criteria
Inclusion Criteria: * Singleton pregnancy * Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia Exclusion Criteria: * \>14 weeks gestation * Multiple pregnancy * History of heart disease, stroke, or peripheral arterial disease * Infectious diseases/conditions, such as Hepatitis B/C, HIV, and COVID19
Conditions Glaucoma
Phase PHASE2
Enrollment 110
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Gen 2 Travoprost Intracameral Implant — travoprost
  • Drug: Timolol eye drops 0.5% — timolol 0.5%
  • Procedure: Sham Procedure — sham implant administration
  • Other: Placebo eye drops — artificial tears

Primary Outcomes

  • Intraocular pressure (IOP) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-12
Completion: 2032-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Glaukos Corporation
Principal Investigators:
  • Luis G. Vargas, MD (STUDY_CHAIR) - Glaukos Corporation
Contact Information
Study Contact:
Study Director
949-739-8749
ClinicalResearch@glaukos.com
Study Coordinator
949-739-8749
ClinicalResearch@glaukos.com
Glaukos Investigative Site
Study Coordinator
949-739-8749
ClinicalResearch@glaukos.com
Glaukos Investigative Site
Interventions
  • Drug: Gen 2 Travoprost Intracameral Implant — travoprost
  • Drug: Timolol eye drops 0.5% — timolol 0.5%
  • Procedure: Sham Procedure — sham implant administration
  • Other: Placebo eye drops — artificial tears
Study Locations (3 sites)
Glaukos Investigative Site, Grand Junction, Colorado 81501 United States
Glaukos Investigative Site, Oklahoma City, Oklahoma 73112 United States
Glaukos Clinical Site, El Paso, Texas 79922 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Home BP Monitoring

NCT05552547
Recruiting
Conditions High Blood Pressure
Phase NA
Enrollment 750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Most cases of high blood pressure in teens are missed for a number of reasons. One reason is that the most common way to make a diagnosis is to make three or more blood pressure measurements in a doctor's office on separate days. This can be inconvenient. Also, measuring blood pressure in the office might be inaccurate, since children (including teens) might have high values in the office but normal values at home. For these reasons, investigators wish to study a different way to identify teens with high blood pressure. Home BP measurements have been used in Europe to make a diagnosis, but not yet in the United States, and never in a higher risk population of teens. African American teens are at higher risk for high blood pressure than other teens. Investigators will compare the values received from the home BP machines to another method (24 hour ambulatory BP monitoring or ABPM) which is the best standard for diagnosis. Investigators also want to learn more about participants experience and their child's experience with both methods. A small sample of participating teens and parents will be invited to participate in short telephone interviews. This study plans to enroll a total of 750 teens at UH. Recruitment will not take place from other organizations.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: Home Blood Pressure Machine — Participants will be asked to measure blood pressure twice daily for three days in a row at home.
  • Device: 24-Hour Blood Pressure Machine — Participants will be asked to wear the machine for 24 hours.

Primary Outcomes

  • Number of participants who meet criteria for hypertension based on average home BP reading. (Up to 2 weeks)
  • Number of participants who meet criteria for hypertension based on 24-hour ambulatory BP reading. (Up to 24 hours)
  • Percent agreement between home BP-reading based diagnosis versus 24-hour ABPM (Up to 2 weeks)
  • True positive rate -- Number of home bp positives over ABPM positives (Up to 2 weeks)
  • True negative rate -- Number of home bp negatives over ABPM negatives (Up to 2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-01
Completion: 2026-09-30
Eligibility
Age: 13 Years – 18 Years
Sex: ALL
Volunteers: true
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospitals Cleveland Medical Center
Principal Investigators:
  • Rao Goutham, MD (PRINCIPAL_INVESTIGATOR) - University Hospitals Cleveland Medical Center
Contact Information
Study Contact:
Goutham Rao, MD
(216)844-3791
goutham.rao@uhhospitals.org
Goutham Rao, MD
(216)844-3791
Goutham.Rao@UHhospitals.org
University Hospitals Cleveland Medical Center
Interventions
  • Device: Home Blood Pressure Machine — Participants will be asked to measure blood pressure twice daily for three days in a row at home.
  • Device: 24-Hour Blood Pressure Machine — Participants will be asked to wear the machine for 24 hours.
Study Locations (1 sites)
University Hospitals Cleveland Medical Center, Cleveland, Ohio 44106 United States
Eligibility Criteria
Inclusion Criteria: * Self-identify or identified by a parent as African-American or of partly African American ancestry Exclusion Criteria: * Prior hypertension diagnosis * Prescribed BP medication * History of congenital heart disease * History of solid organ transplant * Prescribed and using stimulants and other medications on a regular basis known to raise blood pressure such as testosterone and nicotine replacement
Conditions Chronic Kidney Diseases, Type 2 Diabetes...
Phase Not Applicable
Enrollment 1200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA). Key shortcomings of available data on CKD in SSA are as follows: (i) Available data are based on single measurements and, therefore, cannot distinguish between harmless transient deterioration in kidney function and chronic kidney damage; (ii) Accurate information regarding renal protein loss, an important and early marker of kidney disease, is lacking; (iii) Cardiovascular risk factors for CKD, such as obesity, hypertension and diabetes, are often not searched for. Likewise non-classic potential risk factors, such as endemic infectious diseases, socioeconomic status and lifestyle have not been consistently recorded; (iv) Information to interrogate linked interaction over time between risk factors and development of CKD is unavailable. With this project, situated in a region representative of semi-rural SSA, we aim to fill this knowledge gap and (i) establish guideline conform prevalence data of CKD and its major cardiovascular risk factors, as well as (ii) prospectively define the incidence of cardiovascular- and non-classic risk factors of CKD. The data from (i) and (ii) is used to develop predictive models. A prospective cohort of 1200 individuals in a primary care facility will serve as study population. The population is representing a society in transition from rural to more urban lifestyle. In the pilot study, participants will be followed for one years and undergo the clinical and biomedical testing required to capture CKD and its classic and non-classic risk factors over time.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Chronic kidney disease (CKD) prevalence rates (18 months)
  • Prevalence of cardiovascular and non-classic risk factors of CKD (18 months)
  • Incidence of chronic kidney disease (CKD) and cardiovascular- and non-classic risk factors of CKD: (18 months)
  • Incidence of cardiovascular- and non-classic risk factors of CKD: (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-21
Completion: 2026-12-31
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Swiss Tropical & Public Health Institute
Collaborators: University Hospital, Basel, Switzerland, Ifakara Health Institute
Principal Investigators:
  • Michael Mayr, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Basel, Switzerland
  • Daniel H Paris, Prof (PRINCIPAL_INVESTIGATOR) - Swiss Tropical & Public Health Institute
  • Nikolai C Hodel, MSc (PRINCIPAL_INVESTIGATOR) - Swiss Tropical & Public Health Institute
Contact Information
Study Contact:
Nikolai C Hodel, MSc
+255762768035
nikolai.hodel@swisstph.ch
Ally Olotu, PhD
+255718927104
aolotu@ihi.or.tz
Kandy Lussingu, MD
+255716633913
klussingu@yahoo.com
Bagamoyo District Hospital
Interventions
N/A
Study Locations (1 sites)
Bagamoyo District Hospital, Bagamoyo, Pwani Region Tanzania
Eligibility Criteria
Inclusion Criteria: all adult patients (≥18 years) attending the outpatients department of the Bagamoyo district hospital (BDH) or the associated Fukayosi and Yombo dispensary Exclusion Criteria: * \<18 years of age * not living in the BDH catchment area * not of African decent * not willing to come back for follow-up visits
Conditions Esophageal Varices
Phase NA
Enrollment 339
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of early postoperative oral intake (with a fasting period of 6 hours) versus delayed postoperative oral intake (with fasting periods of 24 hours or 48 hours) in patients with cirrhosis undergoing esophageal variceal ligation therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Other: fasting periods of 24 hours — Post-balloon occlusion procedure: fasting for 24 hours
  • Other: fasting periods of 48 hours — Post-balloon occlusion procedure: fasting for 48 hours
  • Other: fasting periods of 6 hours — Post-balloon occlusion procedure: fasting for 6 hours

Primary Outcomes

  • Rate of early postoperative rebleeding (Week 0-6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-20
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 339 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Zhengzhou University
Contact Information
Study Contact:
Hongxia Liang
18595871806
hxliang@zzu.edu.cn
Yuzhong Wang
The Fifth People's Hospital of Anyang
Yuliang Zhao
The Secend People's Hospital of Jiaozuo
Interventions
  • Other: fasting periods of 24 hours — Post-balloon occlusion procedure: fasting for 24 hours
  • Other: fasting periods of 48 hours — Post-balloon occlusion procedure: fasting for 48 hours
  • Other: fasting periods of 6 hours — Post-balloon occlusion procedure: fasting for 6 hours
Study Locations (12 sites)
The Fifth People's Hospital of Anyang, Anyang, China
The Secend People's Hospital of Jiaozuo, Jiaozuo, China
Huaihe Hospital of Henan University, Kaifeng, China
Luohe Central Hospital, Luohe, China
Luoyang Central Hospital, Luoyang, China
Nanyang Central Hospital, Nanyang, China
Sanmenxia Central Hospital, Sanmenxia, China
Shangqiu Municipal Hospital, Shangqiu, China
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
Xuchang Central Hospital, Xuchang, China
Eligibility Criteria
Inclusion Criteria: -1. The patient must be aged\>18 years; 2. The diagnosis of portal hypertension must be confirmed, with gastroscopy revealing severe esophageal varices and a positive red sign; 3. For patients undergoing endoscopic variceal ligation (EVL) due to esophageal varices (including those with hemorrhage or those eligible for elective ligation), successful intraoperative ligation is achieved (achieving hemostasis or completing the predetermined ligation procedure). 4\. Sign the informed consent form Exclusion Criteria: * 1\. Uncontrolled active bleeding or concurrent bleeding from gastric fundal varices; 2.History of prior TIPS, EVL, or surgical shunt procedures; 3. Presence of severe systemic diseases, such as sepsis, uremia, or advanced hepatocellular carcinoma (HCC); 4.Mechanical ventilation with retained catheter, inability to take oral intake, or significant dysphagia, or a history of major esophageal/gastric surgery that has impaired swallowing function; 5. Severe hepatic failure: Child-Pugh score\>13; profound jaundice (serum bilirubin\>10 mg/dL) accompanied by altered consciousness beyond Stage II or massive ascites; 6.Pregnancy or lactation; 7. Inability to provide informed consent.

Placental Imaging Techniques

NCT06861309
Recruiting
Conditions Fetal Growth Restriction (FGR), Placenta...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this proof-of-concept, case-control, clinical trial is to evaluate the efficacy of using two newer ultrasound technologies, quantitative ultrasound (QUS) and ultrafast power Doppler imaging (uPDI), to evaluate the health of the placenta, visualize blood flow through the placental vasculature by color Doppler imaging in singleton pregnancies with and without fetal growth restriction (FGR). * Our primary objective is to investigate the ability of using these ultrasound technologies to distinguish healthy pregnancies from those affected by FGR, a condition characterized by a fetal weight below the 10th percentile for the gestational age or abdominal circumference of the pregnancy. * Secondary aims include longitudinal evaluation of differences in QUS and uPDI imaging over gestation and changes in these measures with evolution of utero-placental insufficiency including with the development of abnormal umbilical-artery Doppler testing, diagnosis of severe FGR, identification of stillbirth, and detection of preeclampsia or preterm birth. Investigators will compare QUS/uPDI imaging and values in pregnancies determined to be healthy by approved, standard-of-care growth ultrasounds to those diagnosed with FGR. Participants will receive research ultrasounds with the experimental Verasonics Vantage 256 system (Verasonics, Inc, Kirkland, WA) utilizing uPDI/QUS every three weeks following their routine growth ultrasound evaluation until delivery. Demographic, obstetric, and delivery-related information, as well as portions of subjects' past medical history will be utilized by researchers to further contextualize imaging and variables gathered during the research ultrasounds.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) — All study participants, regardless of arm, will receive a combine ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) research exam with the Verasonics Vantage 256 (Verasonics, Inc, Kirkland, WA) every three weeks from their routine growth ultrasound until delivery.

Primary Outcomes

  • Number of spiral arteries detected by ultrasound (40 weeks)
  • Velocity of spiral artery jets detected by ultrasound (40 weeks)
  • Speed of sound detected by Quantitative Ultrasound (40 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-23
Completion: 2026-11
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Carilion Clinic
Collaborators: Virginia Polytechnic Institute and State University
Principal Investigators:
  • Megan D Whitham, MD (PRINCIPAL_INVESTIGATOR) - Carilion Clinic
Contact Information
Study Contact:
Megan D Whitham, MD
540-985-9985
mdwhitham@carilionclinic.org
Nicholas Joseph, CCRC
540-985-8000
ncjoseph@carilionclinic.org
Allison R Durica, MD
540-985-9985
ardurica@carilionclinic.org
Carilion Clinic Maternal Fetal Medicine
Interventions
  • Device: ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) — All study participants, regardless of arm, will receive a combine ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) research exam with the Verasonics Vantage 256 (Verasonics, Inc, Kirkland, WA) every three weeks from their routine growth ultrasound until delivery.
Study Locations (1 sites)
Carilion Clinic Maternal Fetal Medicine, Roanoke, Virginia 24013 United States
Eligibility Criteria
Inclusion Criteria: * Normal-Fetal-Weight Pregnancies Arm: Patient at least 18 to 45 years of age at screening * Normal-Fetal-Weight Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders or growth abnormalities * Normal-Fetal-Weight Pregnancies Arm: Low-risk aneuploidy screening, if performed * Normal-Fetal-Weight Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC) * Normal-Fetal-Weight Pregnancies Arm: Anatomical survey has been performed * Normal-Fetal-Weight Pregnancies Arm: Pregnancy without current fetal growth restriction (FGR) diagnosis * Normal-Fetal-Weight Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Patient at least 18 to 45 years of age at screening * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Low-risk aneuploidy screening, if performed * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC) * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Anatomical survey has been performed * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Pregnancy diagnosed with fetal growth restriction (FGR) by estimated fetal weight \<10th centile or abdominal circumference measurements \<10th centile * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject Exclusion Criteria: * Normal-Fetal-Weight Pregnancies Arm: Multiple gestations * Normal-Fetal-Weight Pregnancies Arm: Known fetal anomaly affecting biometric measurements * Normal-Fetal-Weight Pregnancies Arm: Suspected fetal genetic disorder(s) * Normal-Fetal-Weight Pregnancies Arm: Suspected fetal infection(s) * Normal-Fetal-Weight Pregnancies Arm: Non-English or Spanish-speaking * Normal-Fetal-Weight Pregnancies Arm: Unstable housing or transportation * Normal-Fetal-Weight Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment. * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Multiple gestations * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Known fetal anomaly affecting biometric measurements * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal genetic disorder(s) * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal infection(s) * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-English or Spanish-speaking * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Unstable housing or transportation * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.
Conditions Hypertension, Elevated Blood Pressure, S...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study investigates how isometric exercise training (IET) affects blood pressure in physically inactive adults. Isometric exercise involves sustained muscle contractions without movement-for example, pushing against a fixed object. Previous research has shown that IET may help reduce blood pressure, but the mechanisms involved are not fully understood. The purpose of this study is to assess both the immediate (acute) and long-term (chronic) effects of IET on cardiovascular outcomes. Participants will complete a series of lab-based exercise sessions over several weeks. In these sessions, they will perform repeated bouts of isometric leg extensions while seated on an exercise machine designed to measure muscle force. Throughout the study, researchers will monitor participants' blood pressure, heart rate, and muscle activity. Acute responses-such as post-exercise hypotension (a short-term drop in blood pressure)-will be measured immediately after exercise. Chronic changes, such as resting blood pressure improvements, will be evaluated across the training period. Additional measurements will include heart rate variability (HRV), which gives insight into autonomic nervous system activity, and electromyography (EMG), which tracks muscle fatigue and activation patterns. These data will help explore potential mechanisms behind the cardiovascular benefits of IET. By examining how repeated sessions of isometric exercise influence blood pressure and related physiological responses, this research may support the use of IET as a non-pharmacological strategy for managing or preventing hypertension in physically inactive individuals.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Isometric Exercise Training (IET) — Participants perform four repetitions of 90 degree bilateral isometric leg extensions on a dynamometer at 30% of their maximum voluntary contraction (MVC). Each contraction is held for 2 minutes, with 2-minute rest intervals between bouts. Sessions are performed three times per week for four weeks. This behavioral intervention is designed to investigate the acute and chronic effects of isometric exercise on blood pressure, heart rate variability, and muscle fatigue.
  • Behavioral: Expectation-Enhancing Informational Framing — Participants receive a brief standardized presentation highlighting isometric exercise as an evidence-based intervention for lowering blood pressure. The presentation includes statements designed to enhance outcome expectations based on prior literature and expert framing.

Primary Outcomes

  • Change in Resting Systolic Blood Pressure (Baseline to Post-Intervention (approximately 4 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-21
Completion: 2025-09
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: true
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Canterbury Christ Church University
Principal Investigators:
  • Sean Machak (PRINCIPAL_INVESTIGATOR) - Canterbury Christ Church University
Contact Information
Study Contact:
Sean Machak
+447864658805
s.machak2125@canterbury.ac.uk
Philip Hurst
+44 (0)1227 927700
philip.hurst@canterbury.ac.uk
Sean Machak
+447864658805
s.machak@canterbury.ac.uk
Canterbury Christ Church University
Interventions
  • Behavioral: Isometric Exercise Training (IET) — Participants perform four repetitions of 90 degree bilateral isometric leg extensions on a dynamometer at 30% of their maximum voluntary contraction (MVC). Each contraction is held for 2 minutes, with 2-minute rest intervals between bouts. Sessions are performed three times per week for four weeks. This behavioral intervention is designed to investigate the acute and chronic effects of isometric exercise on blood pressure, heart rate variability, and muscle fatigue.
  • Behavioral: Expectation-Enhancing Informational Framing — Participants receive a brief standardized presentation highlighting isometric exercise as an evidence-based intervention for lowering blood pressure. The presentation includes statements designed to enhance outcome expectations based on prior literature and expert framing.
Study Locations (1 sites)
Canterbury Christ Church University, Canterbury, Kent CT1 1QU United Kingdom
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Self-reported physically inactive or insufficiently active (not meeting current physical activity guidelines) * Not currently engaged in structured resistance or isometric exercise training * Able to attend lab sessions over a 4-week period * Provides written informed consent Exclusion Criteria: * Current diagnosis of hypertension requiring medication * Any known cardiovascular, neurological, or musculoskeletal condition contraindicating isometric exercise * Formal education or professional background in exercise science, physiology, or a related field * Pregnant or planning to become pregnant during the study period * Inability to follow verbal instructions or complete study protocols
Conditions Embryo Transfer, Hypertension, Pregnancy...
Phase PHASE3
Enrollment 276
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Drug: Acetylsalicylic acid — 160mg once a day

Primary Outcomes

  • Mean number of women suffering from pre-eclampsia in the treated and not treated groups. (4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-10-25
Completion: 2026-06-30
Eligibility
Age: 18 Years – 43 Years
Sex: FEMALE
Volunteers: false
Enrollment: 276 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de Liege
Principal Investigators:
  • Laurie Henry (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Régional de la Citadelle
Contact Information
Study Contact:
Julie Collée
+32498973386
julie.collee@uliege.be
Marie Timmermans
marie.timmermans@chuliege.be;
Julie Collée
julie.collee@uliege.be
Centre Hospitalier Universitaire de Liège site Citadelle
Interventions
  • Drug: Acetylsalicylic acid — 160mg once a day
Study Locations (1 sites)
Centre Hospitalier Universitaire de Liège site Citadelle, Liège, Belgium
Eligibility Criteria
Inclusion Criteria: * Healthy women from \[18 - 43\] years-old, planned for a frozen embryo transfer, with natural and modified natural or HRT cycle * Who have given their informed consent * Who have a confirmed pregnancy at week 6 of amenorrhea. Exclusion Criteria: * Women presenting one risk factor for preeclampsia: multiple pregnancy, history of preeclampsia, BMI \> 30, lupus syndrome, preexistent proteinuria, non-treated chronic high blood pressure (\>140/90), antiphospholipid antibody syndrome, diabetes (fasting blood sugar \>126mg/dl) * Contraindication to acetylsalicylic acid (at risk of active hemorrhage (like hemophilia, …); at risk of or who have a gastro-duodenal ulcer; at risk or how have a terminal renal or hepatic in-sufficiency (only if acetylsalicylic acid is given at high dose) * Already treated with acetylsalicylic acid * Treatment with anticoagulants or non-steroid anti-inflammatory drugs
Conditions Hypertension
Phase NA
Enrollment 348
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Several studies describe the existence of an association between sexual dysfunction and high blood pressure (hypertension), most often characterized by a decrease in the number of orgasms and the existence of dyspareunia. Hypertension is a contributing factor, and nonadherence to medication could amplify it. There are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and / or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments. The investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers. The main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Biological: Blood sample for the determination of antihypertensives or their metabolites. — 15 ml of Blood sample for the determination of antihypertensives or their metabolites
  • Behavioral: Questionnaire on sexual activity — Questionnaire on sexual activity in women
  • Behavioral: Scale on hospital anxiety and depression — Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
  • Behavioral: Morisky Questionaire — anti-hypertensive medication compliance questionnaire

Primary Outcomes

  • Analyse of sexual dysfunction (25 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-27
Completion: 2027-07-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Toulouse
Principal Investigators:
  • Delphine LAZARO-VERGE, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Toulouse
Contact Information
Study Contact:
Delphine LAZARO-VERGE
5 61 32 30 68
lazaro.d@chu-toulouse.fr
Delphine LAZARO
5 61 32 30 68
lazaro.d@chu-toulouse.fr
LAZARO Delphine
Audrey TOMASIK
561778597
tomasik.a@chu-toulouse.fr
LAZARO Delphine
Interventions
  • Biological: Blood sample for the determination of antihypertensives or their metabolites. — 15 ml of Blood sample for the determination of antihypertensives or their metabolites
  • Behavioral: Questionnaire on sexual activity — Questionnaire on sexual activity in women
  • Behavioral: Scale on hospital anxiety and depression — Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
  • Behavioral: Morisky Questionaire — anti-hypertensive medication compliance questionnaire
Study Locations (1 sites)
LAZARO Delphine, Toulouse, CHU de Toulouse 31059 France
Eligibility Criteria
Inclusion Criteria: * Women over 18, * Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine, * Having signed the informed consent form. * Beneficiary or affiliated to a French Social insurance Exclusion Criteria: * Patients with bariatric surgery, * Patients under guardianship/trusteeship/protection of justice, * Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.

Registry of Arterial Hypertension

NCT04160533
Recruiting
Conditions Arterial Hypertension
Phase Not Applicable
Enrollment 10400
Locations 17 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The problem of the quality of primary health care medical system for patients with arterial hypertension is acute for the investigator's country, as these diseases are the most common and cause the high mortality of the population. The concept of "quality of primary health care medical system" includes its timeliness, accessibility and provision of medical care to the patient at the modern level, which is determined by the degree of performance by doctors of medical and diagnostic measures corresponding current clinical recommendations. The system of cardiovascular desease registries, established in the Federal State Clinical Hospital of the Russian Federation Ministry of Public Health with the automated analysis of data on examination and treatment, in comparison with clinical Recommendations. It makes possibility to identify shortcomings and develop approaches to improving the provision of medical care to patients in real clinical practice. Comparative analysis of the quality of examination and treatment in different samples of patients with cardiovascular desease, observed in 2018-2020, compared with results of previous years will identify ptrends in the provision of medical care to patients with cardiovascular desease.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Number of patients with blood pressure <140/90 mm Hg (2018 - 2021 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-06-01
Completion: 2026-12
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 10400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Contact Information
Study Contact:
Anna Aksenova, MD
+74954146186
aksenovaannav@gmail.com
Анна Аксенова
89032319955
aksenovaannav@gmail.com
Federal State Budgetary Institution "National Medical Research Center of Cardiology named after academician E.I. Chazov" of the Ministry of Healthcare of the Russian Federation
Interventions
N/A
Study Locations (17 sites)
Federal State Budgetary Institution "National Medical Research Center of Cardiology named after academician E.I. Chazov" of the Ministry of Healthcare of the Russian Federation, Moscow, Moscow Oblast 121552 Russia
State Healthcare Institution "Engels City Polyclinic No. 2, Engel's, Russia
State Healthcare Institution "Engels City Polyclinic No. 4, Engel's, Russia
State budgetary health institution of the Kemerovo region "Kemerovo Regional Clinical Cardiology Dispensary named after Academician L.S. Barbarash, Kemerovo, Russia
State budgetary institution of the ryazan region "regional clinical cardiological dispensary", Ryazan, Russia
Municipal budgetary institution of public health "City polyclinic №1" Taganrog Branch №1, Taganrog, Russia
Municipal budgetary institution of public health "City polyclinic №1" Taganrog Branch №2, Taganrog, Russia
Municipal budgetary institution of public health "City polyclinic №1" Taganrog Branch №3, Taganrog, Russia
Municipal budgetary institution of public health "City polyclinic №1" Taganrog Branch №4, Taganrog, Russia
Municipal budgetary institution of public health "City polyclinic №2" Taganrog Branch №1, Taganrog, Russia
Eligibility Criteria
Inclusion Criteria: The diagnosis of arterial hypertension - Exclusion Criteria: No diagnosis of arterial hypertension \-